1 / 3

Abetimus Sodium (LJP 394)

Abetimus Sodium (LJP 394). a synthetic Toleragen molecule consisting of four double-stranded oligodeoxyribonucleotides attached to nonimmunogenic polyethylene glycol an immunomodulating agent that induces tolerance in B cells directed against double-stranded DNA ( dsDNA )

mali
Download Presentation

Abetimus Sodium (LJP 394)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Abetimus Sodium (LJP 394) • a synthetic Toleragen molecule consisting of four double-stranded oligodeoxyribonucleotides attached to nonimmunogenic polyethylene glycol • an immunomodulating agent that induces tolerance in B cells directed against double-stranded DNA (dsDNA) • by cross-linking surface antibodies, which are thought to be responsible for lupus nephritis in SLE

  2. Abetimus Sodium (LJP 394) • In a study conducted by Alarcon-Segovia et al.(2003), treatment with LJP 394 in patients with high-affinity antibodies to its DNA epitope: • prolonged the time to renal flare • decreased the number of renal flares • required fewer HDCC treatments compared with placebo • The drug also appeared to be well tolerated among the patients treated in the study. Alarcon-Segovia, D. et al.(2003). LJP 394 for the prevention of renal flare in patients with systemic lupus erethematosus. Arthritis & Rheumatism, 48(2) 442-454.

  3. The Euro-Lupus Nephritis Trial • The data from the ELNT indicate that in European SLE patients with proliferative lupus nephritis, a remission-inducing regimen of low-dose IV CYC (cumulative dose 3 gm) followed by AZA achieves clinical results comparable to those obtained with high-dose regimen. • Low-dose intravenouscyclophosphamide could be used as an alternative to a high-doseregimen and was associated with half as many severe infections. • Other advantages include no hospitalization and virtually norisk of premature gonadal failure. Houssiau et al. (2002).Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis tral, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis & Rheumatism, 46(8) 2121-2131.

More Related